Atezolizumab

Generic Name: Atezolizumab

Brand Names: Tecentriq

Drug Type: Biotech

Chemical Formula: -

CAS Number: 1380723-44-3

Unique Ingredient Identifier: 52CMI0WC3Y

Background: Atezolizumab is a humanized monoclonal antibody used to prevent the interaction of PD-L1 and PD-1, removing inhibition of immune responses seen in some cancers. This medication is reserved for patients whose tumors express PD-L1, cannot receive platinum-based chemotherapy, or whose tumors do not respond to platinum-based chemotherapy. Atezolizumab was granted FDA approval on 18 October 2016. In November 2022, the manufacturer (Genentech) voluntarily withdrew the use of atezolizumab for the treatment of urothelial carcinoma, previously approved under the FDA's Accelerated Approval Program. The rest of atezolizumab indications remain unaffected.

Indication: Atezolizumab has approved indications for the following conditions:

Non-Small Cell Lung Cancer (NSCLC)

Small Cell Lung Cancer (SCLC)

Hepatocellular Carcinoma (HCC)

Melanoma

Alveolar Soft Part Sarcoma (ASPS)

Associated Conditions: Metastatic Alveolar Soft Part Sarcoma, Metastatic Hepatocellular Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Nonsmall Cell Lung Cancer, Stage II, Small Cell Lung Cancer (SCLC), Stage IIIA Non Small Cell Lung Cancer, Triple-Negative Breast Cancer, Unresectable Alveolar Soft Part Sarcoma, Unresectable Hepatocellular Carcinoma (HCC), Unresectable Melanoma

Associated Therapies: -

Clinical Trials

Study of TJ004309 in Combination With Atezolizumab (Tecentriq®) in Patients With Advanced or Metastatic Cancer

Phase 1

Conditions: Metastatic Cancer
Solid Tumor

Interventions: Drug: TJ004309
Drug: Atezolizumab

First Posted Date: 2019-02-11

Last Posted Date: 2022-04-01

Lead Sponsor: Tracon Pharmaceuticals Inc.

Target Recruit Count: 36

Registration Number: NCT03835949

Locations: 🇺🇸
The University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
HonorHealth Research Institute, Scottsdale, Arizona, United States
🇺🇸
City of Hope, Duarte, California, United States

and more 1 locations

Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy

Phase 2

Recruiting

Conditions: Localized Prostate Cancer
Prostate Cancer
Prostate Adenocarcinoma

Interventions: Drug: Atezolizumab
Drug: Etrumadenant
Drug: Tocilizumab

First Posted Date: 2019-01-29

Last Posted Date: 2024-08-02

Lead Sponsor: David Oh

Target Recruit Count: 68

Registration Number: NCT03821246

Locations: 🇺🇸
University of California, San Francisco, San Francisco, California, United States
🇺🇸
Alvin J. Siteman Cancer Center at Washington University, Saint Louis, Missouri, United States

Atezolizumab and Bevacizumab in Patients With Recurrent or Metastatic Squamous-cell Carcinoma of the Head and Neck

Phase 2

Active, not recruiting

Conditions: Head and Neck Neoplasms

Interventions: Drug: Atezolizumab
Drug: Bevacizumab

First Posted Date: 2019-01-28

Last Posted Date: 2023-09-28

Lead Sponsor: Centre Leon Berard

Target Recruit Count: 33

Registration Number: NCT03818061

Locations: 🇫🇷
Centre Henri Becquerel, Rouen, France
🇫🇷
Centre Léon Bérard, Lyon, France
🇫🇷
Clinique Mutualiste de l'Estuaire, Saint-Nazaire, France

and more 4 locations

Combination of Targeted and Immunotherapy for Advanced Biliary Tract and Esophagogastric Gastric Cancer

Phase 2

Withdrawn

Conditions: Hepatobiliary Neoplasm
GastroEsophageal Cancer
Esophageal Cancer
Biliary Tract Cancer

Interventions: Drug: DKN-01
Drug: Atezolizumab
Drug: Paclitaxel

First Posted Date: 2019-01-28

Last Posted Date: 2020-02-05

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Registration Number: NCT03818997

Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)

Phase 3

Active, not recruiting

Conditions: Stage I Lung Cancer AJCC v8
Stage II Lung Cancer AJCC v8
Stage III Lung Cancer AJCC v8
Limited Stage Lung Small Cell Carcinoma

Interventions: Radiation: 3-Dimensional Conformal Radiation Therapy
Procedure: Biospecimen Collection
Drug: Atezolizumab
Drug: Carboplatin
Drug: Cisplatin
Drug: Etoposide
Radiation: Intensity-Modulated Radiation Therapy
Other: Quality-of-Life Assessment
Other: Questionnaire Administration

First Posted Date: 2019-01-22

Last Posted Date: 2024-12-27

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 545

Registration Number: NCT03811002

Locations: 🇺🇸
Aspirus Regional Cancer Center, Wausau, Wisconsin, United States
🇺🇸
Aurora Cancer Care-Milwaukee West, Wauwatosa, Wisconsin, United States
🇺🇸
Aurora West Allis Medical Center, West Allis, Wisconsin, United States

and more 542 locations

Combination of Talimogene Laherparepvec With Atezolizumab in Early Breast Cancer

Early Phase 1

Active, not recruiting

Conditions: Breast Cancer

Interventions: Biological: Talimogene laherparepvec
Drug: Atezolizumab

First Posted Date: 2019-01-14

Last Posted Date: 2023-06-22

Lead Sponsor: SOLTI Breast Cancer Research Group

Target Recruit Count: 28

Registration Number: NCT03802604

Locations: 🇪🇸
Hospital Universitari Vall d'Hebrón, Barcelona, Spain
🇪🇸
Hospital Clínico universitario de Valencia, Valencia, Spain
🇪🇸
Centro Integral Oncológico Clara Campal, Madrid, Spain

and more 1 locations

A Study to Evaluate the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer

Phase 1

Completed

Conditions: Breast Cancer

Interventions: Drug: Ipatasertib
Drug: Paclitaxel
Drug: Nab-Paclitaxel
Drug: Atezolizumab
Drug: AC

First Posted Date: 2019-01-11

Last Posted Date: 2024-10-30

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 139

Registration Number: NCT03800836

Locations: 🇺🇸
Pacific Shores Medical Group, Long Beach, California, United States
🇦🇺
St Vincents Hospital; Cardiopulmonary transplant Ambulatory Care Dept, Darlinghurst, New South Wales, Australia
🇦🇺
Austin Hospital, Heidelberg, Victoria, Australia

and more 15 locations

Trial to Evaluate Safety and Efficacy of Vinorelbine With Metronomic Administration in Combination With Atezolizumab as Second-line Treatment for Patients With Stage IV Non-small Cell Lung Cancer

Phase 2

Completed

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: Atezolizumab
Drug: Vinorelbine

First Posted Date: 2019-01-11

Last Posted Date: 2022-05-12

Lead Sponsor: University Hospital, Brest

Target Recruit Count: 80

Registration Number: NCT03801304

Locations: 🇫🇷
CH Aix en Provence, Aix-en-Provence, France
🇫🇷
CLCC Caen, Caen, France
🇫🇷
CH de Créteil, Créteil, France

and more 10 locations

Atezolizumab Plus One-year BCG Bladder Instillation in BCG-naive High-risk Non-muscle Invasive Bladder Cancer Patients

Phase 3

Active, not recruiting

Conditions: Bladder Cancer

Interventions: Drug: BCG
Drug: Atezolizumab

First Posted Date: 2019-01-10

Last Posted Date: 2024-12-11

Lead Sponsor: UNICANCER

Target Recruit Count: 517

Registration Number: NCT03799835

Locations: 🇫🇷
Hôpital Cochin, Paris, France
🇫🇷
Groupe Hospitalier Paris Saint Joseph, Paris, France
🇫🇷
Hôpital privé de la Louvière, Lille, France

and more 35 locations

A Study of Atezolizumab in Unresectable or Advaced Malignant Pleural Mesothelioma

Phase 2

Withdrawn

Conditions: Malignant Pleural Mesothelioma, Unresectable
Malignant Pleural Mesothelioma, Advanced

Interventions: Drug: Atezolizumab

First Posted Date: 2018-12-26

Last Posted Date: 2021-05-13

Lead Sponsor: Health Pharma Professional Research

Registration Number: NCT03786419

Locations: 🇲🇽
Health Pharma Professional Research, Mexico City, Mexico

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy